Dosing reference
Every dose that has been studied in humans
Label dosing for approved drugs, the amounts given in registered trials of investigational drugs, and a plain “none established” everywhere else. No forum numbers, no vendor charts. Every figure cites its source.
22 · FDA label15 · Trial doses71 · None established
Reconstitution guide
Lab steps with photos, syringe units and storage.
How long studies ran
Cycle-length evidence: treatment and follow-up durations.
Combinations
What is actually studied when compounds are paired.
Human dosing quick-reference chart
Click any compound for the cited dosing page, study durations and vial arithmetic.
| Compound | Research area | Status | Human amounts | Route studied | Half-life | Evidence | |
|---|---|---|---|---|---|---|---|
| CJC-1295 (no DAC) | Growth Hormone Axis | Not approved | None established | — | No half-life data specific to the no-DAC form were identified; the albumin-binding DAC form had an estimated half-life of 5.8 to 8.1 days in healthy adults, and the DAC group is the feature that extends it . | C | View |
| CJC-1295 (with DAC) | Growth Hormone Axis | Not approved | None established | — | Estimated half-life of 5.8 to 8.1 days after subcutaneous administration in healthy adults . | B | View |
| GHRP-2 | Growth Hormone Axis | Approved outside the US | None established | — | In a Japanese package insert, the terminal elimination half-life after intravenous administration to healthy adult men was reported as roughly 0.4 to 0.7 hours . | B | View |
| GHRP-6 | Growth Hormone Axis | Not approved | None established | — | — | B | View |
| Hexarelin | Growth Hormone Axis | Not approved | None established | — | — | B | View |
| Ipamorelin | Growth Hormone Axis | Not approved | None established | — | Terminal half-life of about 2 hours in healthy male volunteers after intravenous infusion . | B | View |
| Sermorelin | Growth Hormone Axis | Not approved | None established | — | — | B | View |
| Tesamorelin | Growth Hormone Axis | FDA-approved | 1.28 mg once daily (EGRIFTA WR, 11.6 mg/vial) or 1.4 mg once daily (EGRIFTA SV, 2 mg/vial); the formulations are not substitutable | Subcutaneous injection | Mean elimination half-life about 11 minutes after a single 1.28 mg EGRIFTA WR dose and about 8 minutes after a single 1.4 mg EGRIFTA SV dose (healthy subjects) | A | View |
“Human amounts” is a summary; the dosing page for each compound carries the full cited statements. Compounds approved nowhere show “None established” by policy, whatever is circulated elsewhere. Why.
What every dosing page includes
- Quick-reference card
- Label or trial doses, cited
- How long studies ran
- Who was excluded
- Side effects reported
- Reconstitution arithmetic + syringe chart
- Supplies, storage and handling mistakes
- Regulatory status
- Comparison with related compounds
- Combinations and FAQs
Don’t see a compound?
Tell us what to research next. We add compounds when there are primary sources to cite.